Citigroup’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,956
| Closed | -$28.9K | – | 5881 |
|
|
2024
Q1 | $28.9K | Buy |
1,956
+384
| +24% | +$5.39K | ﹤0.01% | 4909 |
|
|
2023
Q4 | $21.1K | Buy |
1,572
+1,548
| +6,450% | +$19.6K | ﹤0.01% | 4971 |
|
|
2023
Q3 | $296 | Sell |
24
-3,093
| -99% | -$37.5K | ﹤0.01% | 5273 |
|
|
2023
Q2 | $38.3K | Buy |
+3,117
| New | +$39K | ﹤0.01% | 4771 |
|
|
2019
Q3 | – | Sell |
-571
| Closed | -$3K | – | 7973 |
|
|
2019
Q2 | $3K | Hold |
571
| – | – | ﹤0.01% | 7603 |
|
|
2019
Q1 | $3K | Sell |
571
-3,101
| -84% | -$14.3K | ﹤0.01% | 7511 |
|
|
2018
Q4 | $11K | Hold |
3,672
| – | – | ﹤0.01% | 7132 |
|
|
2018
Q3 | $15K | Sell |
3,672
-2,415
| -40% | -$10.2K | ﹤0.01% | 7226 |
|
|
2018
Q2 | $24K | Sell |
6,087
-1,056
| -15% | -$7.01K | ﹤0.01% | 6834 |
|
|
2018
Q1 | $45K | Buy |
7,143
+5,037
| +239% | +$41.7K | ﹤0.01% | 6250 |
|
|
2017
Q4 | $17K | Sell |
2,106
-1,350
| -39% | -$12.6K | ﹤0.01% | 6827 |
|
|
2017
Q3 | $40K | Sell |
3,456
-2,997
| -46% | -$31.5K | ﹤0.01% | 6116 |
|
|
2017
Q2 | $63K | Sell |
6,453
-14,015
| -68% | -$286K | ﹤0.01% | 5647 |
|
|
2017
Q1 | $497K | Sell |
20,468
-36,489
| -64% | -$913K | ﹤0.01% | 3874 |
|
|
2016
Q4 | $1.83M | Buy |
56,957
+46,523
| +446% | +$1.98M | ﹤0.01% | 3059 |
|
|
2016
Q3 | $522K | Buy |
10,434
+6,987
| +203% | +$290K | ﹤0.01% | 3861 |
|
|
2016
Q2 | $146K | Sell |
3,447
-9,899
| -74% | -$539K | ﹤0.01% | 4780 |
|
|
2016
Q1 | $879K | Buy |
13,346
+10,852
| +435% | +$566K | ﹤0.01% | 3489 |
|
|
2015
Q4 | $155K | Sell |
2,494
-8,023
| -76% | -$564K | ﹤0.01% | 4977 |
|
|
2015
Q3 | $704K | Buy |
10,517
+5,466
| +108% | +$446K | ﹤0.01% | 3418 |
|
|
2015
Q2 | $490K | Sell |
5,051
-1,106
| -18% | -$105K | ﹤0.01% | 3724 |
|
|
2015
Q1 | $576K | Sell |
6,157
-1,122
| -15% | -$95.5K | ﹤0.01% | 3603 |
|
|
2014
Q4 | $647K | Buy |
7,279
+4,955
| +213% | +$361K | ﹤0.01% | 3608 |
|
|
2014
Q3 | $160K | Sell |
2,324
-1,138
| -33% | -$60.8K | ﹤0.01% | 4396 |
|
|
2014
Q2 | $198K | Sell |
3,462
-1,615
| -32% | -$82K | ﹤0.01% | 4144 |
|
|
2014
Q1 | $201K | Sell |
5,077
-2,093
| -29% | -$89.6K | ﹤0.01% | 4324 |
|
|
2013
Q4 | $302K | Buy |
7,170
+4,638
| +183% | +$134K | ﹤0.01% | 4271 |
|
|
2013
Q3 | $76K | Buy |
2,532
+1,701
| +205% | +$59.5K | ﹤0.01% | 4950 |
|
|
2013
Q2 | $44K | Buy |
+831
| New | +$36.4K | ﹤0.01% | 5451 |
|
Other funds holding MACK
RA
JC
Citigroup's MACK Position: Q2 2024 in Review
Citigroup sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 1,956 shares — an estimated $28.9K sold.
Citigroup first reported a position in MACK in Q2 2013 and held it in 29 quarters. The position peaked at $1.83M in Q4 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Citigroup reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Citigroup sold 1,956 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $28.9K.
- Citigroup first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Citigroup's Merrimack Pharmaceuticals, Inc. position peaked at $1.83M in Q4 2016.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.